EUCR
Income statement / Annual
Last year (2022), Eucrates Biomedical Acquisition Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Eucrates Biomedical Acquisition Corp.'s net income was $5.54 M.
See Eucrates Biomedical Acquisition Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$743,071.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
$743,071.00
|
$0.00
|
| Other Expenses |
$698,578.00
|
$0.00
|
$8,594.00
|
| Operating Expenses |
$698,578.00
|
$743,071.00
|
$8,594.00
|
| Cost And Expenses |
$698,578.00
|
$743,071.00
|
$8,594.00
|
| Interest Income |
$701,134.00
|
$35,761.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
-$1.88 M
|
-$4.53 M
|
$206,297.00
|
| EBITDA |
-$2.58 M |
-$5.27 M |
$8,594.00 |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.12 M
|
$4.57 M
|
$0.00
|
| Income Before Tax |
$2.42 M
|
$3.82 M
|
$8,594.00
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
-$3.12 M
|
-$35,761.00
|
$0.00
|
| Net Income |
$5.54 M
|
$3.82 M
|
$8,594.00
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
1.86 |
1.28 |
0.0006 |
| EPS Diluted |
1.86 |
0.28 |
0.0006 |
| Weighted Average Shares Out |
$2.98 M
|
$13.46 M
|
$13.46 M
|
| Weighted Average Shares Out Diluted |
$2.98 M
|
$13.46 M
|
$13.46 M
|
| Link |
|
|
|
